Ovoca Bio plc

LSE OVB.L

Ovoca Bio plc Gross Profit Margin for the year ending December 31, 2023

Ovoca Bio plc Gross Profit Margin is NA for the year ending December 31, 2023. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.
Key data
Date Gross Profit Margin Operating Income Margin EBT Margin Net Income Margin
Market news
Loading...
LSE: OVB.L

Ovoca Bio plc

CEO Mr. Timothy Rand McCutcheon
IPO Date Jan. 4, 2000
Location Ireland
Headquarters 17 Pembroke Street Upper
Employees 5
Sector Health Care
Industries
Description

Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. It is developing BP-101, a medicinal treatment for premenopausal women with hypoactive sexual desire disorder, which is in phase II clinical study in Australia and New Zealand, and in phase III clinical trials in Russia. It also engages in mineral exploration, as well as provides support services. The company was formerly known as Ovoca Gold plc and changed its name to Ovoca Bio plc in July 2018. Ovoca Bio plc was incorporated in 1985 and is based in Dublin, Ireland.

Similar companies

HEMO.L

Hemogenyx Pharmaceuticals Plc

USD 4.80

0.73%

IMM.L

ImmuPharma plc

USD 0.04

-14.59%

OBD.L

Oxford BioDynamics Plc

USD 0.01

-33.27%

StockViz Staff

January 15, 2025

Any question? Send us an email